"In clinical trials, in patients with primary hypercholesterolaemia [Heterozygous familial hypercholesterolaemia (HeFH) and atherosclerotic cardiovascular disease (CVD)], Repatha reduced LDL-C, TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/apolipoprotein A1 (ApoA1), VLDL-C, TG and Lp(a), and increased...